NBTX Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Nanobiotix S.A. had $36.8M of revenue in fiscal 2025. Over five years, revenue changed +66.6% a year on average.
Last close Β· Oct 23, 2026
$29.36
0.6%Hi! I read Nanobiotix S.A.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
β73.5%
No. It lost money last year.
Does profit turn into cash?
β104.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Nanobiotix S.A. did it, and the next one. Share prices often move a lot on those days.
Next results
March 30, 2027
Tuesday Β· in 155 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Mar 31, 2026 | Period ended Dec 31, 2025 | After the market closes | 20-F β |
| Apr 2, 2025 | Period ended Dec 31, 2024 | After the market closes | 20-F β |
| Apr 24, 2024 | Period ended Dec 31, 2023 | After the market closes | 20-F β |
| Apr 24, 2023 | Period ended Dec 31, 2022 | After the market closes | 20-F β |
| Apr 8, 2022 | Period ended Dec 31, 2021 | After the market closes | 20-F β |
| Apr 7, 2021 | Period ended Dec 31, 2020 | After the market closes | 20-F β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Nanobiotix S.A. had $36.8M of revenue in fiscal 2025. Over five years, revenue changed +66.6% a year on average. Its operating margin was β33.2%, down 984.3Β pts: of every 100 in sales, about β33 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Nanobiotix S.A. lost $27.0M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$38.3M in fiscal 2025, β104.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Nanobiotix S.A. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $95.0M | $44.1M | $83.2M | $51.7M | $62.0M |
| Interest coverage | β67.4x | β3.4x | β1.8x | β9.1x | β0.7x |
| Current ratio | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Quick ratio | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Total assets | $115M | $63.7M | $104M | $70.0M | $79.6M |
| Total liabilities | $84.9M | $92.6M | $106M | $138M | $179M |
| Shareholders' equity | $30.3M | β$28.8M | β$2.0M | β$68.3M | β$99.3M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Nanobiotix S.A. passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 7 | 3 / 7 | 2 / 7 | 2 / 7 | 4 / 7 | 1 / 7 | 3 / 7 |
| Accruals ratio | β8.7% | β17.9% | β6.1% | β14.5% | β23.4% | β35.2% | β60.5% | 14.3% |
| Altman Z'' | β | β | β | β5.50 | β16.32 | β8.89 | β25.76 | β20.39 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.1M | $2.8M | $2.9M | $3.1M | $5.0M | $39.2M | β$7.8M | $36.8M |
| Net interest income | β | β$5.0M | $5.3M | β$0.5M | β$5.9M | β$8.4M | β$8.6M | β$11.6M |
| Research and development | $24.7M | $34.0M | $27.7M | $35.9M | $34.3M | $41.5M | $43.9M | $26.1M |
| Operating income | β$35.5M | β$52.4M | β$41.5M | β$62.2M | β$49.1M | β$29.0M | β$74.0M | β$12.2M |
| Interest expense | $1.0M | $5.0M | β$5.3M | $0.9M | $14.6M | $16.0M | $8.1M | $17.2M |
| Pretax income | β$35.8M | β$57.0M | β$38.3M | β$55.6M | β$60.0M | β$42.9M | β$73.7M | β$27.0M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.0M |
| Net income | β$35.8M | β$57.0M | β$38.3M | β$55.7M | β$60.0M | β$42.9M | β$73.7M | β$27.0M |
| Net income to common | β$35.8M | β$57.0M | β$38.3M | β$55.7M | β$60.0M | β$42.9M | β$73.7M | β$27.0M |
| Diluted EPS | β$1.83 | β$2.63 | β$1.57 | β$1.60 | β$1.72 | β$1.17 | β$1.56 | β$0.56 |
| Diluted shares | 19.63B | 21.63B | 24.39B | 34.73B | 34.85B | 36.93B | 47.27B | 47.82B |
| Cash flow | ||||||||
| Cash from operations | β$30.7M | β$46.1M | β$31.4M | β$35.3M | β$39.0M | β$13.5M | β$21.2M | β$37.7M |
| Capital expenditure | $0.5M | $1.2M | $0.1M | $0.3M | $0.1M | $0.4M | $0.9M | $0.6M |
| Free cash flow | β$31.2M | β$47.3M | β$31.5M | β$35.6M | β$39.1M | β$13.8M | β$22.1M | β$38.3M |
| Depreciation and amortization | $0.7M | $2.0M | $2.0M | $1.8M | $1.6M | $1.6M | $1.8M | $1.7M |
| Stock-based compensation | $2.2M | $4.8M | $3.3M | $3.8M | $3.3M | $3.5M | $4.6M | $4.0M |
| Balance sheet | ||||||||
| Cash and short-term investments | $41.5M | $39.4M | $146M | $95.0M | $44.1M | $83.2M | $51.7M | $62.0M |
| Current assets | $48.7M | $51.8M | $154M | $105M | $55.8M | $96.5M | $63.9M | $73.7M |
| Current liabilities | $13.9M | $16.1M | $23.4M | $41.7M | $40.5M | $55.1M | $61.2M | $67.6M |
| Property and equipment, net | $9.6M | $10.5M | $10.1M | $9.3M | $7.6M | $6.9M | $5.8M | $5.4M |
| Intangible assets | $0.1M | $0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Total assets | $59.1M | $63.1M | $164M | $115M | $63.7M | $104M | $70.0M | $79.6M |
| Total liabilities | $42.8M | $65.3M | $78.0M | $84.9M | $92.6M | $106M | $138M | $179M |
| Shareholders' equity | $16.3M | β$2.1M | $86.5M | $30.3M | β$28.8M | β$2.0M | β$68.3M | β$99.3M |
| Margins | ||||||||
| Operating margin | β864.2% | β1,841.0% | β1,450.1% | β1,986.4% | β977.8% | β74.0% | 951.1% | β33.2% |
| EBITDA margin | β846.4% | β1,771.4% | β1,380.3% | β1,927.4% | β946.4% | β69.8% | 928.5% | β28.6% |
| Net margin | β872.2% | β2,003.7% | β1,337.2% | β1,778.0% | β1,194.3% | β109.6% | 947.5% | β73.5% |
| FCF margin | β758.9% | β1,663.1% | β1,100.1% | β1,137.1% | β778.8% | β35.4% | 283.6% | β104.2% |
| Net interest share of revenue | β | β174.5% | 186.1% | β14.5% | β117.2% | β21.5% | 110.1% | β31.5% |
| Returns | ||||||||
| Return on capital employed | β78.6% | β111.4% | β29.4% | β84.6% | β210.8% | β59.5% | β839.5% | β101.3% |
| Return on equity | β219.6% | β804.7% | β90.8% | β95.3% | β8,013.8% | β | β | β |
| Return on assets | β60.6% | β93.3% | β33.6% | β39.8% | β67.0% | β51.3% | β84.8% | β36.1% |
| Return on tangible equity | β221.1% | β | β44.3% | β183.5% | β | β | β | β |
| Growth | ||||||||
| Revenue growth | β | β30.7% | 0.7% | 9.3% | 60.3% | 680.0% | β119.9% | β |
| Share count change | β | 10.2% | 12.7% | 42.4% | 0.3% | 6.0% | 28.0% | 1.2% |
| Financial health | ||||||||
| Interest coverage | β35.5x | β10.6x | β | β67.4x | β3.4x | β1.8x | β9.1x | β0.7x |
| Current ratio | 3.5x | 3.2x | 6.6x | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Quick ratio | 3.5x | 3.2x | 6.6x | 2.5x | 1.4x | 1.8x | 1.0x | 1.1x |
| Capital allocation | ||||||||
| Capex / revenue | 12.0% | 42.9% | 3.8% | 8.6% | 1.9% | 0.9% | β11.8% | 1.7% |
| Stock comp / revenue | 53.7% | 170.0% | 116.4% | 120.9% | 66.5% | 8.9% | β59.8% | 10.9% |
| Quality scores | ||||||||
| Piotroski F-score | β | 1.0 | 3.0 | 2.0 | 2.0 | 4.0 | 1.0 | 3.0 |
| Altman Z'' | β | β | β | β5.5 | β16.3 | β8.9 | β25.8 | β20.4 |
| Accruals ratio | β8.7% | β17.9% | β6.1% | β14.5% | β23.4% | β35.2% | β60.5% | 14.3% |
Source: SEC EDGAR XBRL filings (CIK 0001760854). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only β not investment advice. Check the original filings before relying on any figure.
